Viatris (VTRS) Other Non-Current Assets (2019 - 2026)
Viatris (VTRS) posted quarterly Other Non-Current Assets of $1.1 billion for Q1 2026, down 51.38% year-over-year from $2.3 billion in Q1 2025, and down 40.92% quarter-over-quarter from $1.9 billion in Q4 2025.
Viatris (VTRS) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 51.38% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (down 51.38% YoY), while the FY2025 annual figure was $1.9 billion, down 20.58% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $1.1 billion, down from $1.9 billion in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.8 billion in Q4 2023, with the low at $230.3 million in Q4 2022.
- The 5-year median for Other Non-Current Assets is $1.9 billion (2025), against an average of $1.8 billion.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets sank 80.33% in 2022, then jumped 1109.73% in 2023.
- Viatris' Other Non-Current Assets stood at $230.3 million in 2022, then surged by 1109.73% to $2.8 billion in 2023, then fell by 15.4% to $2.4 billion in 2024, then dropped by 20.58% to $1.9 billion in 2025, then tumbled by 40.92% to $1.1 billion in 2026.
- Business Quant data shows VTRS's Other Non-Current Assets at $1.1 billion in Q1 2026, $1.9 billion in Q4 2025, and $1.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Bn |
| Mar 31, 2026 | 1.11 Bn |
| Dec 31, 2025 | 1.87 Bn |
| Sep 30, 2025 | 1.89 Bn |
| Jun 30, 2025 | 2.00 Bn |
| Mar 31, 2025 | 2.27 Bn |
| Dec 31, 2024 | 2.36 Bn |
| Jun 30, 2024 | 2.45 Bn |
| Mar 31, 2024 | 2.52 Bn |
| Dec 31, 2023 | 2.79 Bn |
| Sep 30, 2023 | 427.30 Mn |
| Jun 30, 2023 | 2.35 Bn |
| Mar 31, 2023 | 2.42 Bn |
| Dec 31, 2022 | 230.30 Mn |
| Sep 30, 2022 | 1.43 Bn |
| Jun 30, 2022 | 1.47 Bn |
| Mar 31, 2022 | 1.34 Bn |
| Dec 31, 2021 | 1.17 Bn |
| Sep 30, 2021 | 1.04 Bn |
| Jun 30, 2021 | 1.03 Bn |